Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced the appointment of Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer. Dr. Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis, and retinal diseases.